Comparative Pharmacology
Head-to-head clinical analysis: CHLORHEXIDINE GLUCONATE versus HIBISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORHEXIDINE GLUCONATE versus HIBISTAT.
CHLORHEXIDINE GLUCONATE vs HIBISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cationic bisbiguanide that disrupts microbial cell membranes by binding to negatively charged cell wall components, increasing permeability and causing leakage of cytoplasmic contents; also inhibits bacterial enzymes and precipitates cytoplasmic constituents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Active against susceptible gram-positive bacteria.
Oral rinse: 15 mL of 0.12% solution swished in mouth for 30 seconds twice daily; topical: apply 2% cream or lotion to affected area 2-3 times daily.
1.5 mg/kg intravenously every 6 hours; maximum 120 mg per dose.
None Documented
None Documented
Terminal half-life approximately 12-24 hours; may be prolonged in hepatic impairment.
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Primarily renal (10-30% unchanged) and biliary/fecal (majority as metabolites).
Approximately 90% of absorbed dose excreted renally as unchanged drug; <5% in feces via biliary elimination.
Category C
Category C
Antiseptic
Antiseptic